Point-of-Care Hematology


Kelly Mabry, PhD – CEO

Kelly Mabry is a technical leader passionate about bringing meaningful technologies from lab to market. She has developed comprehensive product development plans with a strong product foundation, developed supply chain & manufacturing strategies, and shaped regulatory submissions. She served as the Director of Research and Development at Tangible Science, where she led the development of medical devices from inception through development and on to FDA clearance and commercialization. A chemical engineer by training, she has worked at the interface of engineering, materials science, biology, and medicine. Dr. Mabry received her PhD from the University of Colorado at Boulder and BS from Cornell University.

Paco Robles, PhD – CSO

Dr. Robles is an expert in optical imaging and spectroscopy for biological applications and has pioneered several new techniques for label-free imaging and spectroscopic methods to gain access to novel forms of functional and molecular contrast for a variety of biomedical applications. In addition to serving as CSO, Dr. Robles is an Assistant Professor in the Department of Biomedical Engineering at Georgia Tech and Emory University. Dr. Robles received his PhD in Medical Physics from Duke University.

Wilbur Lam, MD, PhD – CMO

Dr. Lam is a Professor in the Department of Pediatrics at Emory University and in the Department of Biomedical Engineering at Georgia Tech. Dr. Lam earned his PhD in Bioengineering from the University of California, Berkley. Prior to obtaining his PhD, Dr. Lam received his MD from Baylor College of Medicine. He completed his Fellowship in Pediatric Hematology/Oncology and Residency in Pediatrics at the University of California, San Francisco. Dr. Lam’s research interests involve developing and applying novel technologies using micro/nanotechnology, microfluidics, and cell mechanics to research, diagnose, and treat hematologic and oncologic processes.

Board of Directors

Michael Artinger, PhD – Executive Chair

Dr. Artinger is an experienced life science professional, with decades of his career dedicated to creating new, life-saving therapeutics and vaccines. He is EVP and Managing Director of VIC Technology Venture Development, which creates and develops innovative life science companies based on technologies exclusively licensed from top research institutions worldwide. Examples of prior roles include high-impact positions at Sartorius, University of California, Decision Resources, and Genome Therapeutics. Dr. Artinger conducted his postdoctoral training at Harvard Medical School, and received his PhD and BA from the University of California where he was an NSF Undergraduate Research Fellow.

Calvin Goforth, PhD – Director

Dr. Goforth has extensive experience in start-up company development in founder, investor, board member, and executive roles. In these roles, he has raised tens of $millions in capital, helped bring several high value products from concept to market, and helped bring multiple companies to exit events. He received a BS in Aerospace Engineering with Highest Honors from the University of Texas at Austin. Early in his career, Dr. Goforth held positions at NASA (where he worked alternate semesters while pursuing his BS) and Rocketdyne, where he worked in the space shuttle main engine performance analysis group. He later received his PhD in Mechanical Engineering with a minor in Electrical Engineering from Stanford University. He then returned to his home state of Arkansas and took a position as an Assistant Professor in Mechanical Engineering at the University of Arkansas. There, he received the school’s Halliburton Outstanding Researcher Award in Mechanical Engineering for three straight years.

Fenel Eloi, MBA

Fenel is a seasoned executive in the Life Sciences Sector. He was most recently the COO of Cell Signaling Technology, Inc., a privately held Life Sciences company, where he grew the business at a CAGR of 15% over a period of 12 years and provided leadership in the transformation of the company to a global operation. Prior to that, he was the COO of Interleukin Genetics, Inc., a formerly NASDAQ-listed diagnostic company, for 5 years. Prior to Interleukin, he was CFO at LifeCell and Genome Therapeutics, both formerly NASDAQ-listed companies, for a combined period of twelve years. During his professional career, Fenel has scaled up operations, expanded businesses both organically and through strategic partnerships and completed a number of public and private financing transactions.  His leadership experience spans various sizes of companies from start-ups to multinationals. Fenel has an MBA and a BA in Business and Finance.